


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)

Claim 2 (currently amended): A method of treating a warm-blooded animal having a hyperparathyroidism disease comprising which consists essentially of treating the warm-blooded animal by administering a therapeutically effective amount of from 0.5 to 7.5 mg/m² of an epothilone derivative of formula I



wherein A represents O or NR_n, wherein R_n is hydrogen or lower alkyl, R is methyl hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, every 18 to 24 days.

Claim 3 (original): The method according to claim 2 wherein the warm-blooded animal is a human.

Claim 4 (cancelled)

Claim 5 (cancelled):


Claim 6 (previously presented): The method according to claim 2 wherein the hyperparathyroidism disease is adenoma, hyperplasia or carcinoma.

Claim 7 (original): The method according to claim 6 wherein the disease is parathyroid adenoma, parathyroid hyperplasia or parathyroid carcinoma.

Claim 8 (currently amended): The method according to claim 7 wherein the disease is recurrent or persistent parathyroid adenoma, recurrent or persistent parathyroid hyperplasia or recurrent or persistent parathyroid carcinoma.

Claim 9 (previously presented): The method according to claim 2 wherein the hyperparathyroidism disease is primary or secondary hyperparathyroidism.

Claim 10 (currently amended): A method for the treatment of hypercalcemia resulting from a disease selected from parathyroid adenoma, parathyroid hyperplasia or parathyroid carcinoma comprising which consists essentially of treating the disease by administering a therapeutically effective amount of from 0.5 to 7.5 mg/m² of an epothilone derivative of formula I



wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is methyl hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O, or a pharmaceutically acceptable salt thereof to a warm-blooded animal in need thereof every 18 to 24 days.


Claim 11 (original): The method according to claim 10 wherein the warm-blooded animal is a human.

Claim 12 (cancelled)

Claim 13 (cancelled)


Claim 14 (previously presented): The method according to claim 10 wherein the disease is recurrent or persistent parathyroid adenoma, recurrent or persistent parathyroid hyperplasia or recurrent or persistent parathyroid carcinoma.

Claim 15 (withdrawn): A pharmaceutical composition comprising a quantity of compound of formula I



wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, which is therapeutically effective against hyperparathyroidism.

Claim 16 (withdrawn): A commercial package comprising a compound of formula I



wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, together with instructions for use thereof in the treatment of hyperparathyroidism.